×
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
NASDAQ:GH

Guardant Health Stock Forecast, Price & News

$42.26
-2.15 (-4.84%)
(As of 06/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$41.82
$44.89
50-Day Range
$28.82
$69.95
52-Week Range
$27.65
$133.82
Volume
947,724 shs
Average Volume
1.33 million shs
Market Capitalization
$4.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$126.90
30 days | 90 days | 365 days | Advanced Chart

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock Forecast (MarketRank)

Overall MarketRank

2.09 out of 5 stars

Medical Sector

493rd out of 1,436 stocks

Medical Laboratories Industry

15th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Guardant Health logo

About Guardant Health (NASDAQ:GH)

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

GH Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,373
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$126.90
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+200.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
10 Analysts

Profitability

Net Income
$-405.67 million
Net Margins
-107.20%
Pretax Margin
-102.40%

Debt

Sales & Book Value

Annual Sales
$373.65 million
Book Value
$6.34 per share

Miscellaneous

Free Float
96,011,000
Market Cap
$4.31 billion
Optionable
Not Optionable
Beta
0.73














Guardant Health Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2022?

10 analysts have issued twelve-month price targets for Guardant Health's stock. Their GH stock forecasts range from $65.00 to $165.00. On average, they anticipate Guardant Health's share price to reach $126.90 in the next year. This suggests a possible upside of 200.3% from the stock's current price.
View analysts' price targets for Guardant Health
or view top-rated stocks among Wall Street analysts.

How has Guardant Health's stock performed in 2022?

Guardant Health's stock was trading at $100.02 at the beginning of the year. Since then, GH stock has decreased by 57.7% and is now trading at $42.26.
View the best growth stocks for 2022 here
.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Guardant Health
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its earnings results on Thursday, May, 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.02. The business earned $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. Guardant Health had a negative trailing twelve-month return on equity of 62.68% and a negative net margin of 107.20%. Guardant Health's quarterly revenue was up 22.2% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share.
View Guardant Health's earnings history
.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2022 earnings guidance on Monday, May, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.93 million.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, Co-CEO & Chairman (Age 43, Pay $13.66k)
  • Dr. AmirAli Talasaz Ph.D., Co-CEO & Director (Age 42, Pay $13.27k)
  • Mr. Michael Bell, Chief Financial Officer (Age 53, Pay $1.2M)
  • Mr. John G. Saia, Chief Legal Officer (Age 49, Pay $641.22k)
  • Dr. Craig Eagle M.D., Chief Medical Officer (Age 55, Pay $2.88M)
  • Mr. Christopher Freeman, Chief Commercial Officer of Oncology Bus. (Age 48, Pay $740.23k)
  • Mr. Andy Ament, Sr. VP of Operations
  • Darya Chudova, Sr. VP of Technology
  • Mr. Kumud Kalia, Chief Information Officer
  • Ms. Jennifer Higgins, VP of Public Affairs

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.59%), Capital International Investors (4.99%), Capital Research Global Investors (3.93%), Clearbridge Investments LLC (3.29%), Goldman Sachs Group Inc. (1.66%) and Massachusetts Financial Services Co. MA (1.18%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health
.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Capital Research Global Investors, Russell Investments Group Ltd., Zurcher Kantonalbank Zurich Cantonalbank , Chevy Chase Trust Holdings Inc., Group One Trading L.P., RTW Investments LP, and LA Financiere DE L Echiquier. Company insiders that have sold Guardant Health company stock in the last two years include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health
or view top insider-selling stocks.

Which major investors are buying Guardant Health stock?

GH stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Steadfast Capital Management LP, RA Capital Management L.P., Alyeska Investment Group L.P., Ensign Peak Advisors Inc, Blue Water Life Science Advisors LP, Clearbridge Investments LLC, and Artemis Investment Management LLP.
View insider buying and selling activity for Guardant Health
or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $42.26.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $4.31 billion and generates $373.65 million in revenue each year. The company earns $-405.67 million in net income (profit) each year or ($4.12) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for Guardant Health is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at [email protected], or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.